罗氏报告13例达菲抵抗的甲型流感
2009-09-09 20:59:27   来源:丁香园   作者:  评论:0 点击:

BASEL, Switzerland – Swiss pharmaceutical giant Roche Holding AG said Monday that it has had reports of 13 cases of pandemic swine flu becoming resistant to Tamiflu, which it calls a very low percentage.
瑞士,BASEL-瑞士制药巨头罗氏控股公司周一称,目前已有13例猪流感患者出现对达菲的耐药现象,这引起了较低的流行。
A good sign is that the people who had the resistant strain have not passed the disease on to other people, said David Reddy, leader of Roche's Tamiflu pandemic task force. And the resistant variety has been like the widespread version of the virus in that it typically produces only mild symptoms.
罗氏公司达菲流行特别部的David Reddy说,好的方面是:这些感染抗药株的患者并没有将疾病传给其他人。并且耐药变体可能是病毒广泛分布的类型之一,其通常引起轻度症状。

The 13 cases were scattered around the world in Europe, the United States and Asia, said Reddy.
这13例病例散在分布于世界各地,包括欧洲、美国、亚洲。

Tamiflu, whose generic name is oseltamivir, is one of two main antivirals in the arsenal against swine flu as the world awaits the widespread availability of a vaccine against the disease.
达菲,通常称“奥斯他韦”,是在获得可供全球广泛使用的抗病毒疫苗前,两种主要的抗击猪流感的抗病毒药物之一。

Reddy told reporters that the low rate of resistance was in line with tests the company has conducted, which indicated that 0.32 percent of adults and 4 percent of children who took the Roche drug developed resistance to it.
Reddy告诉记者,公司正在对这种低度抗药性进行检测,研究表明服用罗氏药物的人群中,0.32%的成人以及4%的儿童会出现抗药性。

Roche is keeping a close watch on the virus' interaction with the drug, one of the first defenses against the disease, he said.
他说,罗氏密切关注药物与病毒的相互作用,药物是该病的第一道防线。

Reddy told The Associated Press that it wasn't certain why the 13 patients developed the resistance while taking the drug, but that there was an indication that many were taking only half a dose.
Reddy告诉美联社的记者,尚不确定为什么有13为患者在服药期间出现耐药,但是数据表明,许多人仅服用半剂量的药物。

That lower dose is what is given to people to prevent them catching the disease, said Reddy. "If they were actually infected with the virus, the dosage of the drug may have been too low."
人们在预防疾病感染的过程中,服用非常低剂量的额药物,Reddy说,“如果他们真的感染病毒,这个剂量的药物可能实在太少了。”

The company is therefore recommending that doctors prescribe the treatment dose and not the prevention dose if the patient has any symptoms at all.
因此,公司建议医生,如果患者出现任何可以症状,应给予治疗剂量的药物而非预防剂量。

He said the drug was still useful as a preventive at the half-dose strength and that it could be taken for up to six weeks if used for that purpose.
他说,仍可用半剂量的本要进行预防,并且如果因该目的服药,患者可服用药物长达6周。

William M. Burns, chief executive of the Roche pharma division, said the company was ready to crank up production of the drug to 400 million individual treatment packages if needed as the pandemic virus is expected to spread in the Northern Hemisphere this winter.
罗氏药物分部的首席执行官William M. Burns说,如果今年冬天在北半球会出现预期的病毒流行,他们已经准备好生产供4亿人治疗使用的药物,

Another Roche official, Catherine Steele, said the company has been able to extend the shelf life of Tamiflu stockpiles to seven years from five, and it has also developed a way to extract the active ingredient from expiring stockpiles and reprocess them into new capsules to save money for developing countries.
罗氏的另一位官员Catherin Steele谈到,他们已经能够将达菲的储存时间从5年延长至7年,并且还研发一种可以从过期药物中提取有效成分的方法,从而重新将这些有效成分装入新胶囊以降低发展中国家的花费。

-----------------------------------
瑞士,BASEL-瑞士制药巨头罗氏控股公司周一称,目前已有13例猪流感患者出现对达菲的耐药现象,这引起了较低的流行。

罗氏公司达菲流行特别部的David Reddy说,好的方面是:这些感染抗药株的患者并没有将疾病传给其他人。并且耐药变体可能是病毒广泛分布的类型之一,其通常引起轻度症状。

这13例病例散在分布于世界各地,包括欧洲、美国、亚洲。

达菲,通常称“奥斯他韦”,是在获得可供全球广泛使用的抗病毒疫苗前,两种主要的抗击猪流感的抗病毒药物之一。

Reddy告诉记者,公司正在对这种低度抗药性进行检测,研究表明服用罗氏药物的人群中,0.32%的成人以及4%的儿童会出现抗药性。

他说,罗氏密切关注药物与病毒的相互作用,药物是该病的第一道防线。

Reddy告诉美联社的记者,尚不确定为什么有13为患者在服药期间出现耐药,但是数据表明,许多人仅服用半剂量的药物。

人们在预防疾病感染的过程中,服用非常低剂量的额药物,Reddy说,“如果他们真的感染病毒,这个剂量的药物可能实在太少了。”

因此,公司建议医生,如果患者出现任何可以症状,应给予治疗剂量的药物而非预防剂量。

他说,仍可用半剂量的本要进行预防,并且如果因该目的服药,患者可服用药物长达6周。

罗氏药物分部的首席执行官William M. Burns说,如果今年冬天在北半球会出现预期的病毒流行,他们已经准备好生产供4亿人治疗使用的药物,

罗氏的另一位官员Catherin Steele谈到,他们已经能够将达菲的储存时间从5年延长至7年,并且还研发一种可以从过期药物中提取有效成分的方法,从而重新将这些有效成分装入新胶囊以降低发展中国家的花费。

相关热词搜索:罗氏 达菲 甲型

上一篇:《技术评论》09年度世界顶尖青年创新家
下一篇:肥胖、吸烟增加女性罹患乳腺癌的风险

医学推广
热门购物